Pinatuzumab vedotin

Drug Profile

Pinatuzumab vedotin

Alternative Names: ACD22-VCMMAE; Anti-CD22-ADC; Anti-CD22-MCC-DM1; DCDT 2980S ADC; DCDT 2980S antibody-drug conjugate; DCDT-2980S; FCU-2703; RG-7593; RO-5541072; RO-5541072-000

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 24 Apr 2015 Genentech completes phase I trial for B-cell non-Hodgkin's lymphoma & Chronic lymphocytic leukaemia (Combination therapy, Relapsed/refractory disease) in USA (NCT01209130)
  • 06 Feb 2015 Discontinued - Phase-II for Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in Canada (IV)
  • 28 Jan 2015 Discontinued - Phase-I for Chronic lymphocytic leukaemia (Combination therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top